Catalent, Inc. (NYSE:CTLT) Position Lifted by Melqart Asset Management UK Ltd

Melqart Asset Management UK Ltd raised its stake in Catalent, Inc. (NYSE:CTLT) by 159.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,030,240 shares of the company’s stock after buying an additional 632,515 shares during the period. Catalent comprises 5.6% of Melqart Asset Management UK Ltd’s holdings, making the stock its 7th biggest holding. Melqart Asset Management UK Ltd owned about 0.57% of Catalent worth $62,402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in CTLT. Nisa Investment Advisors LLC increased its stake in shares of Catalent by 1.7% during the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after buying an additional 185 shares during the period. GAMMA Investing LLC increased its position in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after purchasing an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after purchasing an additional 229 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Catalent by 3.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after purchasing an additional 278 shares in the last quarter.

Insiders Place Their Bets

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,114 shares of company stock worth $305,931. Company insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.5 %

NYSE:CTLT opened at $61.72 on Wednesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company’s fifty day moving average price is $59.96 and its 200-day moving average price is $58.60. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $62.08. The firm has a market capitalization of $11.20 billion, a P/E ratio of -27.31, a PEG ratio of 2.44 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.10) EPS. As a group, equities research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CTLT shares. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research note on Monday. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Eight investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.